What should be considered in a premenopausal woman with an intrauterine device (IUD) who has had continuous bleeding for six months after years of no bleeding?

Evaluation of Prolonged Bleeding in a Premenopausal IUD User

A premenopausal woman with an IUD who develops continuous bleeding for 6 months after years of amenorrhea requires immediate evaluation for structural uterine pathology—specifically endometrial polyps, fibroids, adenomyosis, hyperplasia, or malignancy—before attributing symptoms to the IUD alone. 1

Diagnostic Priorities

Rule Out Structural Pathology First

• Transvaginal ultrasound is the first-line imaging modality to assess for endometrial polyps, leiomyomas, adenomyosis, and endometrial thickness in any premenopausal woman with abnormal uterine bleeding. 1

• The American College of Radiology identifies polyps, adenomyosis, and leiomyomas as the most common structural causes of abnormal uterine bleeding in premenopausal women, making imaging essential before assuming the IUD is the sole cause. 1

• If transvaginal ultrasound cannot completely visualize the endometrium (due to patient body habitus, uterine position, or presence of fibroids/adenomyosis), MRI with diffusion-weighted imaging should be considered to fully evaluate the endometrium and myometrium. 1

• Endometrial sampling should be strongly considered in this patient given her age and the change in bleeding pattern, particularly if she has risk factors for endometrial cancer (obesity, anovulation, unopposed estrogen exposure). 1

Consider IUD-Related Causes

• The type of IUD matters critically: If this is a copper IUD, increased menstrual bleeding is expected and common 2, 3, but 6 months of continuous bleeding after years of no bleeding represents a significant change that warrants investigation beyond typical IUD side effects.

• If this is a levonorgestrel IUD (LNG-IUD), the clinical picture is particularly concerning because LNG-IUDs typically cause amenorrhea or light bleeding 4, 5, making prolonged bleeding after years of amenorrhea highly atypical and suggestive of either device malposition, expulsion, or underlying pathology.

• Up to 60% of LNG-IUD users discontinue within 5 years due to bleeding irregularities, but this typically occurs early in use, not after years of amenorrhea. 5

Assess for Device Complications

• Verify IUD position via ultrasound to exclude partial expulsion or malposition, which can cause abnormal bleeding patterns.

• Evaluate for infection or endometritis, particularly if the patient has risk factors for sexually transmitted infections or signs of pelvic inflammatory disease.

Management Algorithm After Structural Pathology is Excluded

For Copper IUD Users with Confirmed Normal Anatomy

• Tranexamic acid 1.3 g three times daily for up to 5 days per menstrual cycle is the preferred non-hormonal therapy for heavy menstrual bleeding when no structural pathology is identified. 6

• NSAIDs (mefenamic acid or naproxen) given for 5-7 days during menstruation may reduce menstrual blood loss in copper IUD users, though evidence quality is limited. 6, 4, 2

• Vitamin B1 demonstrated reduction in both pad usage and bleeding days compared to placebo in copper IUD users with heavy bleeding. 4

For LNG-IUD Users with Confirmed Normal Anatomy

• Naproxen may be effective for prophylactic treatment of bleeding immediately after LNG-IUD insertion (<12 weeks), but evidence for treating established bleeding after years of use is lacking. 5

• Estradiol supplementation may be effective in treating ongoing bleeding irregularities >6 months after LNG-IUD insertion, though evidence quality is low. 5

• The evidence for medical treatment of ongoing bleeding irregularities during established LNG-IUD use is severely limited, and device removal with alternative contraception may be more appropriate if structural pathology is excluded. 5

Critical Clinical Pitfalls

• Do not assume the IUD is the cause without imaging and appropriate workup—the change from amenorrhea to 6 months of continuous bleeding is a red flag for structural or malignant pathology. 1

• Tranexamic acid is absolutely contraindicated in patients with active thromboembolic disease or personal history of thrombosis, per FDA labeling. 6

• Combined hormonal contraceptives should not be used to manage bleeding if the patient has contraindications including history of thromboembolism, migraines with aura, uncontrolled hypertension, or complicated valvular heart disease. 7

• If bleeding persists despite appropriate medical management and normal imaging, strongly consider endometrial sampling and/or device removal with transition to alternative contraception (subdermal implant, depot medroxyprogesterone acetate, or combined oral contraceptives if no contraindications exist). 8, 7